About AUTL

AboutAutolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AUTL is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 253.3 M 2.53294E+08 234 234 0.03% 0.00025704 135 K 134566
UBIO Proshares UltraPro Nasdaq Biotechnology 32.1 M 3.21064E+07 228 228 0.01% 0.000148423 15 K 15104
IBB iShares Nasdaq Biotechnology Index Fund 8.5 B 8.4781E+09 222 222 0.06% 0.0006 4.9 M 4906140

Wait, Before You Leave...